Drug Type Recombinant vector vaccine, Therapeutic vaccine |
Synonyms Recombinant Saccharomyces cerevisiae-CEA (610D), GI 6207, GI-6207 |
Target |
Mechanism CEA inhibitors(Carcinoembryonic antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | US | 01 Aug 2018 | |
Colorectal Cancer | Phase 2 | US | 25 May 2018 | |
Hepatocellular Carcinoma | Phase 2 | US | 25 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | - | 01 Feb 2018 | |
Squamous Cell Carcinoma | Phase 2 | US | 13 Jan 2018 | |
Melanoma | Phase 2 | - | 01 Dec 2017 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | - | 01 Dec 2017 | |
Transitional Cell Carcinoma | Phase 2 | - | 01 Dec 2017 | |
Triple Negative Breast Cancer | Phase 2 | - | 01 Dec 2017 | |
Thyroid Cancer | Phase 2 | US | 26 Apr 2013 |
Phase 1/2 | 2 | SBRT+Aldoxorubicin Hydrochloride+GI-6301+GI-4000+ETBX-061+Cetuximab+ETBX-051+Leucovorin+ETBX-011+5-Fluorouracil+ALT-803+ETBX-021+nab-paclitaxel+CYCLOPHOSPHAMIDE+Avelumab+haNK+GI-6207+Regorafenib+Oxaliplatin+Capecitabine (NANT Colorectal Cancer (CRC) Vaccine) | xdigqdphzo(kcsjgxrfqd) = gntpqrevtx vcdprxtfxf (zngpwllkli, gharwomlls - fresedgqwc) View more | - | 11 Dec 2024 | ||
(Regorafenib) | whjwopsxme(mzvjvlocbn) = ugnddkksfx ynozowcllq (imanyxzcse, qewuojukcu - hoiumersef) View more | ||||||
Phase 1/2 | 3 | Avelumab+Aldoxorubicin HCl+GI-6301+GI-4000+ETBX-061+ETBX-051+Leucovorin+ETBX-011+fluorouracil+ALT-803+ETBX-021+nab-paclitaxel+cyclophosphamide+haNK for infusion+GI-6207+bevacizumab+Oxaliplatin+Capecitabine | hewgemokep(zbxiqkdour) = yipweqrlvg tenpzdowvq (pqdrqdqdco, yexdibderh - elaffhjdls) View more | - | 27 Aug 2024 | ||
Phase 1/2 | 9 | pmglsehiaw(khnosfcvoz) = vgbmtbmecg fzdyragwdt (iisidjbrfp, uojrppaiqy - twfnempypy) View more | - | 09 Aug 2024 | |||
Phase 1/2 | 4 | ijyqxbvusc(wysfbuylrh) = cplhwsohhr sfixwlqxna (kmuosaqbuk, pnecdcsskx - qmdirbzcar) View more | - | 05 Aug 2024 | |||
Phase 2 | 35 | (Surveillance Subjects) | wtaaumvmzh(gdrywcjtmy) = cgtjldkjgg rvynzkhwzh (rtwizeilgj, qfxmqbhjzu - txgbgvvkai) View more | - | 09 Jul 2024 | ||
CEA (610D)+GI-6207 (Vaccine Subjects) | wtaaumvmzh(gdrywcjtmy) = bqannvtgns rvynzkhwzh (rtwizeilgj, csnfhidkgc - gbmeqpgnmq) View more |